Compare Amgen, Inc. (AMGN) vs Citigroup Inc. (C) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Citigroup Inc. — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Citigroup Inc. trades at $141.33 (market cap $240.13B). The key difference: Citigroup Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | C | |
|---|---|---|
Market Cap | $196.12B | $240.13B |
Sector | Health | Financials |
52-Week High | $388.16 | $145.67 |
52-Week Low | $271.18 | $86.73 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Citigroup (C) trades at $140.60, up 0.75% today, with neutral technical signals and a consensus analyst price target of $153.15. Recent Q1 2026 earnings beat expectations with EPS of $3.06 versus $2.65. The stock shows improving fundamentals with revenue growth from $85.21B in 2025 to projected $88.3B in 2026 and net income margin expanding to 16.78%. Recent corporate developments include expansion into 24/7 USD clearing services and membership in London Precious Metals Clearing Limited, enhancing its global banking capabilities.
Outlook remains cautiously optimistic with 59% analyst buy ratings, though risks include volatile cash flows from operations and high debt levels. The upcoming Q2 2026 earnings report on July 14 is a key catalyst. Investment opportunity lies in continued execution on profitability improvements and global market expansion, balanced against macroeconomic sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
